We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+46.36%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$7.86B
AUM Growth
+$1.46B
Cap. Flow
+$137M
Cap. Flow %
1.74%
Top 10 Hldgs %
51.1%
Holding
83
New
21
Increased
18
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$142M
2
DYN icon
Dyne Therapeutics
DYN
+$112M
3
EVH icon
Evolent Health
EVH
+$102M
4
LENZ
LENZ Therapeutics
LENZ
+$86.9M
5
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$71.7M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$704M
2
CBAY
Cymabay Therapeutics
CBAY
+$164M
3
ICVX
Icosavax, Inc. Common Stock
ICVX
+$94M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$93.6M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$76.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Miscellaneous 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMSW icon
76
NewAmsterdam Pharma Warrant
NAMSW
$52.3M
$3.68M 0.05%
333,333
– –
CNTB
77
Connect Biopharma Holdings
CNTB
$73.7M
– –
-3,062,871
Closed -$3.61M
SABS icon
78
SAB Biotherapeutics
SABS
$310M
– –
-237,408
Closed -$1.63M
ALPN
79
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-4,909,763
Closed -$93.6M
CBAY
80
DELISTED
Cymabay Therapeutics
CBAY
– –
-6,940,000
Closed -$164M
ICVX
81
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-5,963,565
Closed -$94M
IMGN
82
DELISTED
Immunogen Inc
IMGN
– –
-23,750,601
Closed -$704M
HARP
83
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-1,500,000
Closed -$17.1M
1 2 3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, RA Capital Management held 83 positions worth $7.86B, up 23% from $6.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management's Q1 2024 filing shows 21 new, 18 increased, 5 reduced and 7 closed positions. Its largest new stake was Edgewise Therapeutics: 8,909,091 shares worth $163M. The largest sale was Immunogen Inc, an estimated $704M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • RA Capital Management's largest Q1 2024 buy was Edgewise Therapeutics: 8,909,091 shares worth $163M.
  • RA Capital Management added most to Evolent Health in Q1 2024, an estimated $102M increase.
  • RA Capital Management's biggest Q1 2024 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $76.4M.
  • RA Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $704M.
  • RA Capital Management's ten largest holdings make up 51% of its $7.86B portfolio in Q1 2024.
  • RA Capital Management opened 21 new positions and closed 7 in Q1 2024.
  • RA Capital Management's portfolio value rose 23% quarter-over-quarter to $7.86B.

Based on RA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.